Autonomix Announces Reverse Stock Split
Autonomix Medical, Inc. has announced a 1-for-21 reverse stock split of its common stock, effective from June 24, 2026. Following the split, approximately 11.4 million shares will be consolidated into around 543,000 shares. The company focuses on innovative medical technologies for treating nervous system diseases, initially targeting pain associated with pancreatic cancer.
THE WOODLANDS, TX, June 18, 2026 (GLOBE NEWSWIRE) — Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that it filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a 1-for-21 reverse stock split of its common stock. The reverse stock split will take effect at 12:01 am (Eastern Time) on June 24, 2026, and the Company’s common stock will open for trading on The Nasdaq Capital Market on June 24, 2026 on a post-split basis, under the existing ticker symbol “AMIX” but with a new CUSIP number 05330T304.